With the increase of life expectancy in our country and the increasing environmental pollution, the incidence of cancer is increasing year by year, and we are facing the dual challenge of reducing the incidence of cancer and improving the survival rate of cancer. Tumor immunotherapy, as the fourth...

A well-known international authoritative journal in the field of clinical lung cancer diagnosis and treatment, "Clinical Lung Cancer", published a report about ACTL targeted cellular immunotherapy (ACTL) for the treatment of non-small cell lung adenocarcinoma (NSCLC) brain metastase...

 On September 18, 2017, the 14th Scientist Forum co-sponsored by China Future Research Association, China High-tech Industrialization Research Association, China Technology Market Association, and Discovery Magazine was held in Beijing Convention Center. The theme of this...

On September 21, 2017, the 2017 Shenzhen International Biology/Life and Health Industry Exhibition (hereinafter referred to as "Bio Expo") officially kicked off at the Shenzhen Convention and Exhibition Center. Wang Weizhong, Member of the Standing Committee of the Guangdong Pr...

On April 28, 2017, the signing ceremony of the ACTL technology project cooperation between Shenzhen Yishi Kangning Biotechnology Co., Ltd. and Singapore World Health Group (REGENE GROUP) was successfully held. Mr. Chai Xiaorong, Chairman of ISKCON, and Mr. Liu ...